학술논문
Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study.
Document Type
Academic Journal
Author
Conte C; Clinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.; Inserm Unit 1027, University of Toulouse 3, Toulouse, France.; Clinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.; Vayr F; Clinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.; Occupational Diseases Department, Toulouse University Hospital, Toulouse, France.; Pajiep MC; Clinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.; Inserm Unit 1027, University of Toulouse 3, Toulouse, France.; Clinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.; Despas F; Clinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.; Inserm Unit 1027, University of Toulouse 3, Toulouse, France.; Clinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.; Huguet F; Department of Haematology, Toulouse University Hospital, IUCT-O, Toulouse, France.; Mestre ML; Clinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.; Inserm Unit 1027, University of Toulouse 3, Toulouse, France.; Clinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.; Gauthier M; Department of Internal Medicine and Haematology, CH Cahors, Cahors, France. martin.gauthier@hotmail.fr.; Haematology Department, Centre Hospitalier de Cahors, 52, place Antonin Bergon, 46000, Cahors, France. martin.gauthier@hotmail.fr.; Herin F; Clinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.; Occupational Diseases Department, Toulouse University Hospital, Toulouse, France.
Source
Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
Background: The advent of chronic myeloid leukaemia (CML) tyrosine-kinase inhibitors (TKI) has led to new paradigms including occupational rehabilitation.
Objectives: This study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients.
Methods: A cohort of all 18-60-year-old newly diagnosed CML patients initiating a TKI between January 1st 2011 and December 31 st 2014 in France was identified in the French National Healthcare database (Système National des Données de Santé [SNDS]). Patients with a sick leave identified in the 24 months after TKI initiation were compared with sex and initiation date matched controls in a nested case-control design. Factors associated with sick leaves were identified through a conditional logistic regression model, providing adjusted odds-ratio (OR) with their 95% confidence interval (CI).
Results: Among 646 18-60-year-old patients, 268 were prescribed at least one sick leave in the study period, with 176 (27.2%) having their first sick leave prescribed after TKI initiation. The median number of sick days over the 2-years period was 115 per patient (interquartile range 25.5-384.5). In the nested case-control study (176 cases and 176 matched controls), sick leaves were more likely observed with second generation TKI (OR 4.11 [1.80-9.38]), whereas they were less likely observed in case if social deprivation (OR 0.07 [0.02-0.28].
Conclusion: More than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Objectives: This study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients.
Methods: A cohort of all 18-60-year-old newly diagnosed CML patients initiating a TKI between January 1
Results: Among 646 18-60-year-old patients, 268 were prescribed at least one sick leave in the study period, with 176 (27.2%) having their first sick leave prescribed after TKI initiation. The median number of sick days over the 2-years period was 115 per patient (interquartile range 25.5-384.5). In the nested case-control study (176 cases and 176 matched controls), sick leaves were more likely observed with second generation TKI (OR 4.11 [1.80-9.38]), whereas they were less likely observed in case if social deprivation (OR 0.07 [0.02-0.28].
Conclusion: More than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)